肿瘤细胞治疗研究
英文原题：Advances and challenges in CAR-T therapy for glioblastoma.
胶质母细胞瘤（GBM）仍是最致命的原发性脑肿瘤之一，当前标准疗法带来的生存获益有限。
胶质母细胞瘤（GBM）仍是致死率最高的原发性脑肿瘤之一，现行标准治疗仅带来有限生存获益。尽管免疫治疗拓展了治疗选择，其疗效尚未表现出一致性和持久性。嵌合抗原受体（CAR）T细胞疗法作为一种有前景的平台，可能克服现有策略的关键局限。本综述强调CAR-T疗法与标准治疗及免疫治疗互补的独特优势，总结迄今已报告的临床结局，包括已完成和正在进行的试验，并指出反复出现的障碍，如抗原异质性、持久性有限及高度免疫抑制性肿瘤微环境。针对这些挑战，综述讨论了推进GBM CAR-T治疗的新策略，包括扩大抗原识别范围、增强效应功能、改善安全性及探索替代细胞平台。随着持续创新和严格临床评估，CAR-T疗法有望为GBM患者带来有意义且持久的获益。
Glioblastoma (GBM) remains one of the most lethal primary brain tumors, with current standard therapies conferring only limited survival benefit. Although immunotherapeutic approaches have expanded treatment options, they have yet to demonstrate consistent and durable efficacy. Chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising platform with the potential to overcome critical limitations of existing strategies. This review highlights the unique advantages of CAR-T therapy in complementing both standard and immune-based treatments. It further summarizes clinical outcomes reported to date, encompassing completed and ongoing trials, and underscores recurring barriers such as antigen heterogeneity, limited persistence, and the profoundly immunosuppressive tumor microenvironment. In view of these challenges, we discuss emerging strategies to advance CAR-T therapy in GBM, including approaches to broaden antigen recognition, enhance effector function, improve safety, and explore alternative cellular platforms. With continued innovation and rigorous clinical evaluation, CAR-T therapy holds considerable promise for delivering meaningful and durable benefit to patients with GBM.
MEMBER ACCOUNT
登录成功会直接打开下一页。
